TY - JOUR T1 - Aberrant Methylation of T-cadherin Can Be a Diagnostic Biomarker for Colorectal Cancer JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 277 LP - 284 VL - 14 IS - 4 AU - BO-SHI DUAN AU - LONG-FEI XIE AU - YUE WANG Y1 - 2017/07/01 UR - http://cgp.iiarjournals.org/content/14/4/277.abstract N2 - Background/Aim: T-cadherin is a tumor suppressor gene, its predictive value in colorectal cancer (CRC) still remains controversial. In this study, we aimed to evaluate the association between T-cadherin promoter methylation and CRC by performing a meta-analysis. Materials and Methods: The relevant literature was searched using the PubMed, Cochrane Library, Web of Science and Google Scholar databases for articles published until December 2016. The effect sizes were estimated by measuring an odds ratio (OR) with a 95% confidence interval (CI). Sensitivity analysis was performed to examine the heterogeneity and funnel plots were constructed to evaluate publication bias. Results: Nine studies, including 488 samples were included in this meta-analysis. The pooled OR of T-cadherin promoter methylation in cancer tissues was 16.73 (95%CI=6.24-44.87), 19.48 (95%CI=5.64-67.31) and 2.23 (95%CI=1.05-4.75) compared to normal tissues, adjacent tissues and premalignant tissues, respectively. The relationship between T-cadherin promoter methylation and clinicopathological features were also analyzed. However, a significant association was not observed between T-cadherin promoter methylation status and gender, tumor stage, and lymph node status (p>0.05). Conclusion: The methylation status of T-cadherin promoter was strongly associated with CRC risk. However, T-cadherin promoter methylation may have a limited prognostic value for CRC patients. ER -